Biocon’s Stock Tumbles After Rivals Launch Cancer-Drug Biosimilar In U.S.
Kiran Mazumdar-Shaw, chairman and managing director of Biocon (Photographer: Namas Bhojani/Bloomberg)

Biocon’s Stock Tumbles After Rivals Launch Cancer-Drug Biosimilar In U.S.

Shares of Biocon Ltd. dropped the most in nearly a year as Amgen Inc and Allergan Plc launched the first biosimilars of breast-cancer drug trastuzumab in the U.S., denying the Indian company exclus...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.